Cagrilintide
Last reviewed
Also known as: NN9838, AM833
Cagrilintide is a long-acting amylin analog investigated for weight loss, studied in Phase 2 trials for achieving over 10% body weight reduction when combined with semaglutide.
Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinc
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
§ AI Reference Summary
Cagrilintide (also known as NN9838, AM833) is a prominently researched experimental compound classified strictly within the Metabolic framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy. with a documented biological half-life of roughly 168 hours, In preclinical investigative trials and independent academic studies, researchers utilizing Cagrilintide have documented significant, quantifiable biological outcomes, primarily focusing on weight loss, appetite reduction, glycemic control. Typical research protocols investigate administering 500 to 4500mcg via subq pathways weekly. However, it is critically important to understand that while Cagrilintide demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
§ Mechanism of Action
Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy.
§ Primary Benefits
- 1Weight loss
- 2appetite reduction
- 3glycemic control
§ Clinical Evidence
Cagrilintide Phase 2 trial for weight management
Lau et al. (Lancet): Phase 2 RCT showing cagrilintide 4.5mg weekly achieved 10.8% weight loss vs 3.0% placebo at 26 weeks, with acceptable safety profile.
StrongCagriSema (cagrilintide + semaglutide) Phase 2 results
Frias et al. (Lancet): CagriSema combination achieved 15.6% weight loss at 32 weeks in type 2 diabetes patients — superior to either agent alone.
StrongAmylin analogs in obesity management: mechanism review
Review of amylin's role in energy homeostasis and why dual amylin-calcitonin receptor agonists like cagrilintide represent a new weight loss mechanism distinct from GLP-1.
ModerateEfficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
A 2026 randomized controlled trial demonstrated that co-administering cagrilintide and semaglutide resulted in a significantly greater bodyweight reduction (-18.4%) compared to semaglutide alone (-11.9%) over 68 weeks in East Asian adults with overweight or obesity.
Very StrongObesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Next-generation multi-receptor agonists and amylin analogs demonstrated weight reductions of up to 24% and improved metabolic outcomes beyond traditional GLP-1 therapies. A 2026 review investigated these emerging treatments, highlighting a shift toward integrated neuroendocrine and body-composition-focused disease modification.
EmergingChildhood obesity and cardiac risk in youth: Emerging challenges toward 2050.
A 2026 review found that childhood obesity significantly increases cardiovascular risks, and demonstrated that emerging therapies like retatrutide and oral GLP-1 agents are currently under clinical evaluation to improve weight management adherence.
EmergingNew Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.
Structured, mechanism-based nutritional counseling may mitigate gastrointestinal adverse events and improve adherence in patients using incretin-based anti-obesity medications, a 2026 review found. The researchers provided a pragmatic framework combining pharmacology with clinical nutrition to optimize tolerability and patient outcomes.
EmergingMitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
A 2026 in vitro study found that tirzepatide promoted sustained improvements in skeletal muscle mitochondrial respiration under both healthy and lipotoxic conditions. In contrast, semaglutide and cagrilintide demonstrated transient reductions in mitochondrial function that resolved after five days.
PreclinicalEfficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
A 2026 meta-analysis demonstrated that Cagrisema produced significantly greater weight loss than semaglutide, while cagrilintide monotherapy yielded comparable results. The study found the combination therapy offered superior efficacy with a similar overall safety profile, despite slightly higher rates of nausea.
Very StrongCagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
A 2026 meta-analysis found that CagriSema demonstrated superior reductions in body weight, waist circumference, and systolic blood pressure compared to semaglutide monotherapy or placebo. However, the dual therapy was also associated with a higher frequency of gastrointestinal adverse events.
Very Strong§ Safety Profile
Generally well-tolerated in Phase 2 trials. Main side effects are GI-related (nausea, vomiting). Novo Nordisk is developing CagriSema (cagrilintide + semaglutide) as next-gen obesity treatment. Research-only peptide.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
§ Dosing Protocol
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
RouteSubQ
Dose Range500–4500 mcg
FrequencyWeekly
TimingAny time, consistent day
Cycle Length12–24 weeks
Clinical trial doses: 0.3-4.5mg weekly with dose escalation over 4-8 weeks. Start low (0.3-0.6mg) and increase every 4 weeks to minimize GI side effects.
§ Pharmacokinetics
⏱️ Half-Life: 7d
Plasma concentration over time§ Expected Outcomes
Week 1
Appetite suppression begins; reduced food cravings
Weeks 2–4
Measurable weight loss (1-2 lbs/week); improved meal portion control
Month 2–3
10-11% body weight loss at clinical doses; improved glycemic markers
Long-term
Clinical trials show sustained weight loss through 26+ weeks; CagriSema in Phase 3 trials
§ Adverse Effects
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea Most common during dose escalation; typically resolves in 2-4 weeks | ~25% of users | moderate |
Diarrhea | ~10% of users | mild |
Vomiting | ~8% of users | moderate |
Injection site reaction | ~5% of users | mild |
Constipation | ~8% of users | mild |
Where to Source Cagrilintide for Research
Finding verified, high-purity Cagrilintide requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Cagrilintide✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Reconstitution CalculatorCalculate reconstitution for Cagrilintide →
Compare ToolCompare Cagrilintide to similar peptides →
Frequently Asked Questions
Cite This Page
Free Download
2026 Peptide Stack Cheat Sheet
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
§ About the Author
Dr. E. Vance
Editorial Director, PeptiDex
Dr. E. Vance is the Editorial Director at PeptiDex and leads the platform's editorial division, ensuring that every published research summary meets rigorous preclinical citation standards. With a Ph.D. in Molecular Pharmacology from Columbia Univers...
View Full ProfileLast fact-checked: · PeptiDex Editorial Team
⚠ Educational only · Not medical advice · Most peptides are research-only / not FDA-approved